pharma · Dermatitis atopic · Cancer
Sanofi-Aventis U.S
Sanofi-aventis Healthcare Pty Ltd
Sanofi-aventis Healthcare Pty is a pharma organization headquartered in Sydney, AU. Primary therapeutic focus areas include Dermatitis atopic, Cancer, Immune system diseases, Asthma, Chronic Obstructive Pulmonary Disease
Bridgewater, USA HQ
177 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- Bridgewater, USA
- Employees
- 177
- Programs
- 117
- Drugs
- 148
- Patents
- 0
EFC17215 - LEAP2MONO
Phase 3 · small molecule · Gaucher's disease type III
EFC17215 - LEAP2MONO for Gaucher's disease type III is a Phase 3 program (small_molecule) at Sanofi-aventis Healthcare Pty Ltd with 1 ClinicalTrials.gov record(s).
Internal code EFC17215 - LEAP2MONO
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Sanofi-aventis Healthcare Pty Ltd
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Gaucher's disease type III
- Status
- active
- Trials
- 1